Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Chimeric Therapeutics Ltd. ( (AU:CHM) ) has shared an update.
Chimeric Therapeutics Ltd. has announced a change in the interests of its substantial holder, Paul Hopper, as of May 26, 2025. The voting power of Hopper’s fully paid ordinary shares has decreased from 12.4% to 10.2%, indicating a dilution in his stake due to a placement. This change reflects a strategic adjustment in shareholder interests, potentially impacting the company’s market positioning and stakeholder dynamics.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Ltd. operates in the biotechnology industry, focusing on the development of innovative cell therapies for cancer treatment. The company is listed on the Australian Securities Exchange under the ticker CHM.
Technical Sentiment Signal: Sell
Current Market Cap: A$7.4M
For a thorough assessment of CHM stock, go to TipRanks’ Stock Analysis page.